Table 3.

Multivariable analysis to determine factors associated with nodal pCR (ypN0 disease) among patients in trials 40601/40603. (N=493, patients with missing grade[N=32], missing T category [N=13], or missing both grade/T category [N=1] were excluded from the total study population [N=539] for this analysis).

	Events/Total	Odds Ratio (95% CI)	P-value
Treatment arm			0.262
Paclitaxel	62/74	Reference
Paclitaxel and Bevacizumab	48/65	0.38 (0.14, 0.99)	0.0491
Paclitaxel and Carboplatin	55/70	0.54 (0.20, 1.45)	0.221
Paclitaxel, Carboplatin and Bevacizumab	57/68	0.59 (0.20, 1.70)	0.331
Paclitaxel and Trastuzumab	63/87	0.60 (0.24, 1.50)	0.271
Paclitaxel, Trastuzumab and Lapatinib	66/83	0.74 (0.28, 1.94)	0.541
Paclitaxel and Lapatinib	29/46	0.30 (0.11, 0.82)	0.0181
Clinical T category			0.112
1	18/26	Reference
2	251/306	2.42 (0.81, 7.23)	0.121
3	101/146	1.33 (0.44, 4.09)	0.611
4	10/15	1.14 (0.21, 6.37)	0.881
Clinical N category			<0.00012
0	198/223	Reference
1	146/217	0.16 (0.09, 0.30)	<0.00011
2	30/44	0.18 (0.07, 0.47)	0.00041
3	6/9	0.17 (0.03, 1.02)	0.0531
Tumor subtype			12
HER2+	158/216	Reference
TNBC	222/277	1.00 (1.00, 1.00)	11
Tumor grade			0.152
High	304/385	1.18 (0.24, 5.78)	0.841
Intermediate	68/97	0.62 (0.12, 3.25)	0.571
Low	8/11	Reference
In-breast response			<0.00012
RD	155/252	Reference	<0.00011
pCR	225/241	12.55 (6.73, 23.42)

¹Covariate Wald p-value

²Type 3 Wald p-value